Search

Your search keyword '"Pontiroli, Antonio E."' showing total 519 results
Start Over Author "Pontiroli, Antonio E."
519 results on '"Pontiroli, Antonio E."'

3. Advice of General Practitioner, of Surgeon, of Endocrinologist, and Self-determination: the Italian Road to Bariatric Surgery

Author

Pontiroli, Antonio E., Mingrone, Geltrude, Colao, Annamaria, Barrea, Luigi, Cannavale, Giulia, Pinna, Ferdinando, Ceriani, Valerio, De Carli, Stefano Maria, Cesana, Giovanni, Olmi, Stefano, Scolari, Gloria, Sarro, Simonetta, Sarro, Giuliano, Procopio, Claudia, Giovanelli, Alessandro, Morricone, Lelio, Micheletto, Giancarlo, Malavazos, Alexis, Panizzo, Valerio, Plebani, Laura, Zappa, Marco Antonio, Tubazio, Igor, Foschi, Diego, Capogrossi, Silvia, Conte, Caterina, Saibene, Alessandro, Socci, Carlo, Gozza, Martina, Testa, Sara, Marinari, Giuseppe, Maccatrozzo, Stefano, Croci, Marina, Mozzi, Enrico, Verrastro, Ornella, Capristo, Esmeralda, Raffaelli, Marco, Bruni, Vincenzo, Soare, Andrea, Spagnolo, Giuseppe, Manfrini, Silvia, Gallo, Ida, Casella, Giovanni, Castagneto-Gissey, Lidia, Watanabe, Mikiko, Frontoni, Simona, Di Paola, Massimiliano, Russo, Benedetta, Bigarelli, Patrizia, Casella-Mariolo, James R., Filippi, Franca, Leonetti, Frida, Di Biasio, Alberto, Silecchia, Gianfranco, Guglielmi, Valeria, Arcudi, Claudio, Vitiello, Antonio, Musella, Mario, Schiano, Rita, Giardiello, Cristiano, Iovino, Michele Giuseppe, De Palma, Maurizio, Tolone, Salvatore, Docimo, Ludovico, Renzulli, Michele, Pilone, Vincenzo, Police, Maria, Angrisani, Luigi, and Tagliabue, Elena

Published
2022
Full Text
View/download PDF

7. Maternal Salivary miR-423-5p Is Linked to Neonatal Outcomes and Periodontal Status in Cardiovascular-High-Risk Pregnancies.

Author

La Sala, Lucia, Carlini, Valentina, Mandò, Chiara, Anelli, Gaia Maria, Pontiroli, Antonio E., Trabucchi, Emilio, Cetin, Irene, and Abati, Silvio

Subjects
PREGNANCY complications, PREGNANCY outcomes, HEART metabolism disorders, ORAL diseases, PERIODONTAL disease
Abstract

Periodontal disease (PD) during pregnancy may trigger systemic inflammation, increasing the risk of developing cardiometabolic disease (CMD). As a consequence, PD may result in the activation of cellular and molecular pathways, affecting the disease course and pregnancy outcome. Although microRNAs (miRNAs) are considered ideal biomarkers for many diseases, few studies have investigated salivary miRNAs and their role in pregnancy or neonatal outcomes. In this study, we sought to investigate the associations between salivary miRNAs of pregnant women with oral diseases and their effects on neonatal outcomes. Eleven (n = 11) salivary miRNAs from a cohort of pregnant women with oral diseases (n = 32; oral health, H; gingivitis, G; and periodontitis, P) were detected using a previous profiling analysis with an FDR < 0.20 and a fold change (FC) < 0.5 or FC > 2 for the most highly expressed miRNAs. Spearman correlations were performed for 11 salivary microRNAs associated with oral-derived inflammation, which could affect neonatal outcomes during pregnancies at risk for cardiometabolic disease (CMD), defined by the presence of a high pregestational BMI. In addition, ROC curves demonstrated the diagnostic accuracy of the markers used. Upregulation of miR-423-5p expression and a decrease in miR-27b-3p expression were detected in the P-group (p < 0.05), and ROC analysis revealed the diagnostic accuracy of miR-423-5p for discriminating oral diseases, such as gingivitis versus periodontitis (P vs. G, AUC = 0.78, p < 0.05), and for discriminating it from the healthy oral cavity (P vs. H, AUC = 0.9, p < 0.01). In addition, miR-27b-3p and miR-622 were also able to discriminate the healthy group from the P-group (AUC = 0.8, p < 0.05; AUC = 0.8, p < 0.05). miR-483-5p was able to discriminate between the G-group (AUC = 0.9, p < 0.01) and the P-group (AUC = 0.8, p < 0.05). These data support the role of salivary miRNAs as early biomarkers for neonatal outcomes in pregnant women with periodontal disease at high risk for CMD and suggest that there is cross-talk between salivary miRNAs and subclinical systemic inflammation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Correction: Advice of General Practitioner, of Surgeon, of Endocrinologist, and Self-Determination: the Italian Road to Bariatric Surgery

Author

Pontiroli, Antonio E., Mingrone, Geltrude, Colao, Annamaria, Barrea, Luigi, Cannavale, Giulia, Pinna, Ferdinando, Ceriani, Valerio, De Carli, Stefano Maria, Cesana, Giovanni, Olmi, Stefano, Scolari, Gloria, Sarro, Simonetta, Sarro, Giuliano, Procopio, Claudia, Giovanelli, Alessandro, Morricone, Lelio, Micheletto, Giancarlo, Malavazos, Alexis, Panizzo, Valerio, Plebani, Laura, Zappa, Marco Antonio, Tubazio, Igor, Foschi, Diego, Capogrossi, Silvia, Conte, Caterina, Saibene, Alessandro, Socci, Carlo, Gozza, Martina, Testa, Sara, Marinari, Giuseppe, Maccatrozzo, Stefano, Croci, Marina, Mozzi, Enrico, Verrastro, Ornella, Capristo, Esmeralda, Raffaelli, Marco, Bruni, Vincenzo, Soare, Andrea, Spagnolo, Giuseppe, Manfrini, Silvia, Gallo, Ida, Casella, Giovanni, Gissey, Lidia Castagneto, Watanabe, Mikiko, Frontoni, Simona, Di Paola, Massimiliano, Russo, Benedetta, Bigarelli, Patrizia, Mariolo, James R. Casella, Filippi, Franca, Leonetti, Frida, Di Biasio, Alberto, Silecchia, Gianfranco, Guglielmi, Valeria, Arcudi, Claudio, Gentileschi, Paolo, Sbraccia, Paolo, Vitiello, Antonio, Musella, Mario, Schiano, Rita, Giardiello, Cristiano, Iovino, Michele Giuseppe, De Palma, Maurizio, Tolone, Salvatore, Docimo, Ludovico, Renzulli, Michele, Pilone, Vincenzo, Police, Maria, Angrisani, Luigi, and Tagliabue, Elena

Published
2022
Full Text
View/download PDF

11. Effect of influenza vaccination on SARS‐CoV‐2 infection: Relationship between SARS‐CoV‐2 infection rates and effects of influenza vaccination.

Author

Pontiroli, Antonio E., Zanoni, Ivan, Tanzi, Elisabetta, Tagliabue, Elena, and La Sala, Lucia

Subjects
INFLUENZA vaccines, VIRUS diseases, COMBINED ratio, SARS-CoV-2, VACCINATION
Abstract

A recent meta-analysis found that influenza vaccination is associated with a reduced rate of SARS-CoV-2 infection in most studies, although it does not affect hospital admission or mortality. However, a subgroup analysis showed that this association was not observed in studies conducted in Spain compared to those in Italy, the United States, and Canada. The authors suggest that this difference may be due to unidentified country-specific factors. They also hypothesize that the presence of more aggressive SARS-CoV-2 strains or variants of concern (VOCs) in Italy and Spain may contribute to the differences in infection rates. Further research is needed to determine if the immune response from influenza vaccination provides protection against other viral infections. [Extracted from the article]

Published
2024
Full Text
View/download PDF

18. Vaccination against influenza viruses reduces infection, not hospitalization or death, from respiratory COVID‐19: A systematic review and meta‐analysis.

Author

Pontiroli, Antonio E., Scovenna, Francesco, Carlini, Valentina, Tagliabue, Elena, Martin‐Delgado, Jimmy, La Sala, Lucia, Tanzi, Elisabetta, and Zanoni, Ivan

Subjects
SARS-CoV-2, MEDICAL personnel, VIRUS diseases, INFLUENZA vaccines, INFLUENZA viruses
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) causes COVID‐19 and has brought a huge burden in terms of human lives. Strict social distance and influenza vaccination have been recommended to avoid co‐infections between influenza viruses and SARS‐CoV‐2. Scattered reports suggested a protective effect of influenza vaccine on COVID‐19 development and severity. We analyzed 51 studies on the capacity of influenza vaccination to affect infection with SARS‐CoV‐2, hospitalization, admission to Intensive Care Units (ICU), and mortality. All subjects taken into consideration did not receive any anti‐SARS‐CoV‐2 vaccine, although their status with respect to previous infections with SARS‐CoV‐2 is not known. Comparison between vaccinated and not‐vaccinated subjects for each of the four endpoints was expressed as odds ratio (OR), with 95% confidence intervals (CIs); all analyses were performed by DerSimonian and Laird model, and Hartung‐Knapp model when studies were less than 10. In a total of 61 029 936 subjects from 33 studies, influenza vaccination reduced frequency of SARS‐CoV‐2 infection [OR plus 95% CI = 0.70 (0.65−0.77)]. The effect was significant in all studies together, in health care workers and in the general population; distance from influenza vaccination and the type of vaccine were also of importance. In 98 174 subjects from 11 studies, frequency of ICU admission was reduced with influenza vaccination [OR (95% CI) = 0.71 (0.54−0.94)]; the effect was significant in all studies together, in pregnant women and in hospitalized subjects. In contrast, in 4 737 328 subjects from 14 studies hospitalization was not modified [OR (95% CI) = 1.05 (0.82−1.35)], and in 4 139 660 subjects from 19 studies, mortality was not modified [OR (95% CI) = 0.76 (0.26−2.20)]. Our study emphasizes the importance of influenza vaccination in the protection against SARS‐CoV‐2 infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Duodenal adipose tissue is associated with obesity in baboons (Papio sp): a novel site of ectopic fat deposition in non-human primates

Author

Higgins, Paul B., Folli, Franco, Andrade, Marcia C. R., Foster, Jaydee, Mattern, Vicki, Paroni, Rita, Schlabritz-Loutsevitch, Natalia, Voruganti, V. Saroja, Kumar, Shyamesh, Guardado-Mendoza, Rodolfo, Bulfamante, Gaetano, Fiorina, Paolo, Pontiroli, Antonio E., Hubbard, Gene B., Owston, Michael, Dick, Jr., Edward J., and Comuzzie, Anthony G.

Published
2019
Full Text
View/download PDF

29. Additional file 1 of Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons

Author

Pontiroli, Antonio E., Rizzo, Manfredi, and Tagliabue, Elena

Abstract

Additional file 1: Table S1. Persons with diabetes per country in various years. Table S2. Persons with type 1 diabetes per country in various years. Absolute prevalence. Table S3. Glucagon sales (any type, millions of units) in 2019-2021 in countries where new ready-to-use glucagons were or were not available in 2019-2021. Only retail data are considered. Totals and mean ± SD are reported. On the left: sales in countries where new drugs were (Group A) or were not (Group B) available in 2019-2021. On the right: sales in the same countries when new drugs are not considered. Table S4. Glucagon units (any type) by country. Totals and mean ± SD. Retail and hospital sales are considered together. Table S5. Commercial sales of glucagon formulations (any type) by country. Retail and hospital sales are considered together. Figure S1. Persons with type 1 diabetes and glucagon sales (any type, millions of units) in years 2014-2019.Figure S2. Persons with type 1 diabetes and glucagon sales (any type, millions of units) in year 2021; comparison between data on prevalence of type 1 diabetes according to IDF Atlas and to the recent paper (Lancet Diabetes Endocrinol 2022; 10:741).

Published
2023
Full Text
View/download PDF

41. The interferon landscape along the respiratory tract impacts the severity of COVID-19

Author

Sposito, Benedetta, primary, Broggi, Achille, additional, Pandolfi, Laura, additional, Crotta, Stefania, additional, Clementi, Nicola, additional, Ferrarese, Roberto, additional, Sisti, Sofia, additional, Criscuolo, Elena, additional, Spreafico, Roberto, additional, Long, Jaclyn M., additional, Ambrosi, Alessandro, additional, Liu, Enju, additional, Frangipane, Vanessa, additional, Saracino, Laura, additional, Bozzini, Sara, additional, Marongiu, Laura, additional, Facchini, Fabio A., additional, Bottazzi, Andrea, additional, Fossali, Tommaso, additional, Colombo, Riccardo, additional, Clementi, Massimo, additional, Tagliabue, Elena, additional, Chou, Janet, additional, Pontiroli, Antonio E., additional, Meloni, Federica, additional, Wack, Andreas, additional, Mancini, Nicasio, additional, and Zanoni, Ivan, additional

Published
2021
Full Text
View/download PDF

42. Biliopancreatic Diversion (BPD), Long Common Limb Revisional Biliopancreatic Diversion (BPD + LCL–R), Roux-en-Y Gastric Bypass [RYGB] and Sleeve Gastrectomy (SG) mediate differential quantitative changes in body weight and qualitative modifications in body composition: a 5-year study

Author

Ceriani, Valerio, primary, Pinna, Ferdinando, additional, Galantino, Antonio, additional, Zakaria, Ahmed S., additional, Manfrini, Roberto, additional, Pontiroli, Antonio E., additional, and Folli, Franco, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results